Clearside Biomedical (CLSDQ) AI Stock Analysis

• Market Cap: $3.93M
• Dividend Yield: N/A
• Average Volume (3M): 64.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.04
• Revenue Growth: -56.78%
• EPS Growth: 25.16%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -17.10
• Shares Outstanding: 5,233,981
• 10 Day Avg. Volume: 36,098
• 30 Day Avg. Volume: 64,393
• PEG Ratio: 0.18
• Price to Book (P/B): -1.80
• Price to Sales (P/S): 42.14
• P/FCF Ratio: -2.73
• Enterprise Value/Market Cap: -0.62
• Enterprise Value/Revenue: -0.73
• Enterprise Value/Gross Profit: -0.85
• Enterprise Value/Ebitda: 0.17
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $0.71 ▼(-13.54% Downside)

The score is driven primarily by very weak financial performance (large ongoing losses, significant cash burn, and negative equity), reinforced by bearish technicals (price below all key moving averages and negative MACD). Negative corporate events (Chapter 11 process and Nasdaq delisting) further weigh on the outlook, while valuation metrics provide little support due to losses and no stated dividend yield.

Positive Factors

Proprietary delivery technology

Ownership of a specialized SCS Microinjector is a durable competitive asset in posterior-eye therapeutics. It creates differentiation, supports licensing or partnership revenue, and can sustain long-term commercial and collaboration opportunities even if clinical timelines slip.

High gross margins

An ~86% gross margin indicates the underlying delivery technology or products have low direct costs relative to revenue. If commercialized, such margins provide operating leverage, enabling profitability once fixed R&D and SG&A scale down or are restructured over the medium term.

Low reported debt

Minimal formal debt reduces interest and covenant burdens and can simplify restructuring outcomes. Lower secured liabilities may improve recoveries for stakeholders and provide strategic flexibility during turnaround or a sale process compared with heavily leveraged peers.

Negative Factors

Chapter 11 bankruptcy and asset-sale process

A Chapter 11 filing and active asset-sale process fundamentally alter the company's ability to execute long-term plans. Restructuring and potential asset dispositions threaten continuity, reduce value capture for equity holders, and likely end independent commercialization of current programs.

Negative shareholders' equity

Persistently negative equity reflects cumulative operating losses and capital erosion, constraining the firm's ability to raise traditional equity and signaling solvency issues. This structural capital weakness limits strategic options and increases priority claims from creditors in any restructuring.

Sustained cash burn and weak cash generation

Consistent, large negative operating and free cash flows indicate the business cannot self-fund R&D or operations. Over months this drives reliance on external financing or asset sales, elevates bankruptcy risk, and undermines the firm's ability to support long-term development and commercialization.

Clearside Biomedical Business Overview & Revenue Model

Company Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

How the Company Makes Money

Clearside Biomedical generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may involve licensing agreements for its drug delivery technology and product candidates. The company may also earn revenue from milestone payments associated with the advancement of its product candidates through clinical development and regulatory approvals. Additionally, if its therapies are commercialized, Clearside could see revenue from product sales. The company has engaged in strategic collaborations that provide funding and support for its research and development efforts, contributing significantly to its financial resources.

Clearside Biomedical Financial Statement Overview

Summary

Financials indicate severe distress: revenue is modest and down ~20% TTM with multi-year volatility, operating and net losses are very large, and cash burn is heavy (TTM operating cash flow about -$21.3M; free cash flow about -$21.7M). The balance sheet is also impaired with negative equity (about -$54.0M TTM), despite very low reported debt.

Income Statement

TTM (Trailing-Twelve-Months) revenue is modest and down ~20% versus the prior period, extending a volatile multi-year revenue pattern (large 2021 level followed by much lower sales in 2022–2025). While gross margin remains very strong (TTM ~86%), operating losses are extreme (TTM operating loss of ~$23.0M) and net losses are large (TTM net loss of ~$26.0M), indicating the cost structure is far above the current revenue base. Profitability has materially deteriorated from the small profit in 2021 to sustained, heavy losses since 2022.

Balance Sheet

The balance sheet shows significant financial stress: stockholders’ equity is negative in TTM (about -$54.0M) and was also negative in 2023 and 2024, which is a major red flag for solvency and capital structure stability. Positively, reported total debt is very low in TTM (~$0.4M), but the negative equity makes leverage ratios less meaningful and highlights prior balance sheet erosion. Total assets have also shrunk sharply from 2022 to TTM, suggesting a reduced operating cushion.

Cash Flow

Cash generation is weak, with TTM operating cash flow of about -$21.3M and free cash flow of about -$21.7M, implying continued cash burn to fund operations. Free cash flow has not shown sustained improvement (TTM growth is negative), and cash flow remains negative across all shown years. A relative positive is that free cash flow and net loss move closely together in TTM, but the absolute level of burn remains high and raises ongoing financing risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.33M	1.66M	8.23M	1.33M	29.57M	7.89M
Gross Profit	2.85M	1.51M	7.87M	1.12M	29.57M	7.89M
EBITDA	-14.37M	-24.35M	-23.06M	-29.46M	554.00K	-17.70M
Net Income	-26.00M	-34.35M	-32.48M	-32.95M	376.00K	-18.21M
Balance Sheet
Total Assets	11.64M	25.13M	34.02M	51.30M	42.90M	19.32M
Cash, Cash Equivalents and Short-Term Investments	6.80M	20.02M	28.92M	48.42M	30.44M	17.29M
Total Debt	446.00K	52.47M	43.00M	35.26M	675.00K	1.98M
Total Liabilities	65.59M	63.98M	49.93M	40.70M	4.93M	10.56M
Stockholders Equity	-53.95M	-38.85M	-15.91M	10.61M	37.98M	8.76M
Cash Flow
Free Cash Flow	-21.74M	-25.68M	-19.91M	-13.61M	-10.73M	-13.18M
Operating Cash Flow	-21.29M	-24.70M	-18.14M	-13.37M	-10.73M	-13.12M
Investing Cash Flow	9.30M	-638.00K	-1.78M	-246.00K	0.00	-55.00K
Financing Cash Flow	4.91M	16.44M	414.00K	31.33M	23.78M	7.87M

Clearside Biomedical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLSDQ, the sentiment is Negative. The current price of 0.82 is below the 20-day moving average (MA) of 0.92, below the 50-day MA of 0.99, and below the 200-day MA of 6.32, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 41.71 is Neutral, neither overbought nor oversold. The STOCH value of 41.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLSDQ.

Clearside Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RLYB	48 Neutral	$27.12M	-2.01	-21.17%	―	12.71%	79.93%
CING	47 Neutral	$42.74M	-1.09	-284.50%	―	―	93.84%
APVO	43 Neutral	$7.25M	>-0.01	-256.30%	―	―	99.02%
PCSA	41 Neutral	$6.80M	-0.09	-270.74%	―	―	72.88%
CLSDQ	39 Underperform	$3.93M	-0.15	―	―	-56.78%	25.16%
XTLB	39 Underperform	$8.27M	-7.61	―	―	―	65.45%

Clearside Biomedical Corporate Events

Clearside Biomedical Advances Bankruptcy Asset Sale Process

Clearside Biomedical, Inc., which filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware on November 23, 2025, advanced its court-supervised sale process in December 2025 by securing approval of auction and bidding procedures for a sale of all or substantially all of its assets. On December 17, 2025, the company designated Health Ocean Limited, or its assignee, as the stalking horse bidder, and on December 19, 2025, the court approved both the bidding framework and that designation, making the stalking horse offer the minimum bid for any competing proposals. The company also filed its initial monthly operating report for the period November 23–30, 2025, showing no full-time employees, negative equity of roughly $26.9 million, prepetition unsecured debt of about $2.3 million, postpetition debt of about $0.27 million, and a net loss of about $0.49 million for the short reporting period, underscoring the financial distress driving the restructuring and potential asset sale that will be closely watched by creditors and other stakeholders.

The most recent analyst rating on (CLSDQ) stock is a Sell with a $0.66 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSDQ Stock Forecast page.

Clearside Biomedical Delists from Nasdaq Amid Bankruptcy

On December 8, 2025, Clearside Biomedical filed a Form 25 with the SEC to delist its common stock from Nasdaq and terminate its registration under the Exchange Act, following a voluntary Chapter 11 bankruptcy filing. The stock was suspended from Nasdaq trading on December 1, 2025, and began trading on the OTC Pink Limited Market, with the delisting process expected to reduce certain SEC reporting obligations.

The most recent analyst rating on (CLSDQ) stock is a Sell with a $0.78 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSDQ Stock Forecast page.